12:00 AM
 | 
Feb 04, 2013
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Exelixis sales and marketing update

Exelixis launched Cometriq cabozantinib in the U.S. to treat progressive, metastatic medullary thyroid cancer (MTC). The wholesale...

Read the full 71 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >